Neurocrine Biosciences announced a 44% year-over-year increase in net product sales to $811 million in Q1 2026, driven by strong demand for INGREZZA and CRENESSITY. The company reaffirmed its full-year 2026 sales guidance for INGREZZA at $2.7 to $2.8 billion. It also entered a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, adding VYKAT XR for treating hyperphagia in Prader-Willi syndrome, expected to close in Q2 2026. Neurocrine is advancing its pipeline with new clinical trials in schizophrenia and obesity, positioning itself for sustained growth and innovation in neuropsychiatric and endocrine disorders.
VYKAT XR (diazoxide choline) treatment demonstrated significant and lasting improvements in hyperphagia and behavioral symptoms in individuals with Prader-Willi syndrome (PWS) for up to three years. Participants who resumed VYKAT XR after a 16-week w...
Neurocrine Biosciences reported that CRENESSITY (crinecerfont) significantly improved hormone levels and reduced glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency, a rare form of CAH....
Neurocrine Biosciences announced two-year Phase 3 data from the CAHtalyst Pediatric study showing that CRENESSITY (crinecerfont) treatment slows bone age progression and improves predicted adult height in children with classic congenital adrenal hype...
Neurocrine Biosciences announced that two-year data from their Phase 3 CAHtalyst Adult study shows CRENESSITY (crinecerfont) improves cardiometabolic outcomes like insulin resistance, body weight, and bone health in adults with classic congenital adr...
